Menthol 0.1%/Eucalyptus 0.34% Polyglycol Troche Base Lollipop
This lollipop is a troche base formulated for use in treating general cough and cold symptoms. It contains 0.1% Menthol and 0.34% Eucalyptus in a polyglycol base.
Controlled substances must be E-Prescribed. Visit your Tutorials tab to learn how to prescribe.
Formula Information
Our Menthol 0.1%/Eucalyptus 0.34% Polyglycol Troche Base Lollipop is an effective formulation for relieving general cough and cold symptoms. This formulation can be particularly helpful for congestion, dryness, and irritation caused by a common cold. By combining these two active ingredients, menthol and eucalyptus, our lollipop provides a dual action to help clear airways, ease coughing, and reduce symptoms of irritation. The lollipop base provides slow, steady absorption, giving patients a more extended period of relief. Additionally, the delivery method of our lollipop is particularly convenient and often more appealing to younger patients. If you have any questions, please don't hesitate to contact us. We are happy to answer any questions you might have and provide more information on this product and its ingredients.
Drug Interactions
This lollipop is a troche base formulated for use in treating general cough and cold symptoms. It contains 0.1% Menthol and 0.34% Eucalyptus in a polyglycol base.
How Does it Work
Menthol 0.1%/Eucalyptus 0.34% Polyglycol Troche Base Lollipops are designed to provide both short-term symptomatic relief and long-term management of cough and cold symptoms. Upon ingestion, the lollipop slowly releases its active ingredients, menthol and eucalyptus, in the form of a troche which acts as a means of providing sustained delivery of its contents throughout the mouth, throat, and lungs for hours. The menthol acts as a topical anesthetic and decongestant to reduce irritation, inflammation, and any build-up of mucus in the airways. The eucalyptus acts as an expectorant, loosening phlegm and aiding in its expulsion. This combination helps provide an overall decrease in the severity and duration of symptoms associated with a cough and cold. The lollipop base also aids in the sustained release of the ingredients, allowing for a controlled and prolonged delivery of the active ingredients throughout the oral cavity, throat, and lungs.
Other Uses
This compounded formulation of Menthol 0.1%/Eucalyptus 0.34% Polyglycol Troche Base Lollipop may be used to create a palatable form of a medication for use in pediatric patients or patients who have difficulty swallowing standard tablets or capsules. The lollipop form may improve adherence to certain medications, and allow for improved patient compliance and satisfaction. Additionally, the formulation may be used to take advantage of the synergistic effects of the two active ingredients, which may create a more effective product than either alone. This formulation may also act as a safe, palatable alternative to other forms of medication delivery, such as vape pens or transdermal patches, with fewer adverse effects. Lastly, this formulation may be used as a topical anesthetic or analgesic, in order to provide relief of sore throat or irritated mucosa.
Formulas and/or material listed are not to be interpreted as a promise, guarantee or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care, or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.